Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
Rhea-AI Summary
Oncocyte (Nasdaq: OCX), a diagnostics technology company, has scheduled its fourth quarter 2024 financial results announcement for March 24, 2025, after market close. The company will host a live Zoom webinar at 2:00 p.m. PT on the same day to discuss the results, followed by a Q&A session. Investors can access the webinar through registration, and a replay will be available on Oncocyte's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – OCX
On the day this news was published, OCX declined 3.31%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day.
The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q4 2024 Earnings Webinar.
An archived replay will be available after the call concludes on Oncocyte’s investor relations website at https://investors.oncocyte.com.
About Oncocyte
Oncocyte is a leading diagnostics technology company. The company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:
VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/
GraftAssure™ - https://oncocyte.com/graftassure/
DetermaIO™ - https://oncocyte.com/determa-io/
DetermaCNI™ - https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
FAQ
When will Oncocyte (OCX) release its Q4 2024 earnings?
What time is Oncocyte's (OCX) Q4 2024 earnings call?
How can investors access Oncocyte's (OCX) Q4 2024 earnings call?
Where can I find the replay of Oncocyte's (OCX) Q4 2024 earnings call?
